154 related articles for article (PubMed ID: 33894006)
21. Clinical and histologic features associated with lentigo maligna clearance after imiquimod treatment.
Kwak R; Joyce C; Werchniak AE; Lin JY; Tsibris HC
J Dermatolog Treat; 2022 Jun; 33(4):1995-1999. PubMed ID: 34315342
[TBL] [Abstract][Full Text] [Related]
22. Five-year recurrence rate of lentigo maligna after off-label treatment with imiquimod.
Cliff SH
Br J Dermatol; 2016 Jan; 174(1):22-3. PubMed ID: 26790655
[No Abstract] [Full Text] [Related]
23. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream.
van Meurs T; van Doorn R; Kirtschig G
Dermatol Surg; 2007 May; 33(5):623-6; discussion 626-7. PubMed ID: 17451589
[No Abstract] [Full Text] [Related]
24. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):407-412. PubMed ID: 35431054
[TBL] [Abstract][Full Text] [Related]
25. Imiquimod: a novel treatment for lentigo maligna.
Ahmed I; Berth-Jones J
Br J Dermatol; 2000 Oct; 143(4):843-5. PubMed ID: 11069469
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
27. Treatment of lentigo maligna with imiquimod 5% cream.
Hopson B; Richey D; Sajben FP
J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
[TBL] [Abstract][Full Text] [Related]
28. Lentigo maligna and radiotherapy.
Wilson LD
N Engl J Med; 2006 Mar; 354(12):1322; author reply 1322. PubMed ID: 16554541
[No Abstract] [Full Text] [Related]
29. [Lentigo maligna treated with 5% imiquimod cream].
Martín T; Ojeda A; Martínez S; Vera A
Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
[TBL] [Abstract][Full Text] [Related]
30. Image in clinical medicine. Lentigo maligna.
Noel B; Kunzle N
N Engl J Med; 2005 Nov; 353(20):2176. PubMed ID: 16291987
[No Abstract] [Full Text] [Related]
31. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
Woodmansee CS; McCall MW
Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
[No Abstract] [Full Text] [Related]
32. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
[TBL] [Abstract][Full Text] [Related]
33. Imiquimod in the treatment of lentigo maligna.
Rajpar SF; Marsden JR
Br J Dermatol; 2006 Oct; 155(4):653-6. PubMed ID: 16965411
[TBL] [Abstract][Full Text] [Related]
34. Imiquimod for superficial and in situ skin malignancy.
Drug Ther Bull; 2009 Oct; 47(10):113-6. PubMed ID: 19809085
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
36. Topical imiquimod therapy for lentigo maligna.
Mahoney MH; Joseph MG; Temple C
Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
[TBL] [Abstract][Full Text] [Related]
37. Surgical treatments for lentigo maligna: a review.
McLeod M; Choudhary S; Giannakakis G; Nouri K
Dermatol Surg; 2011 Sep; 37(9):1210-28. PubMed ID: 21631635
[TBL] [Abstract][Full Text] [Related]
38. Amelanotic lentigo maligna managed with topical imiquimod.
Lapresta A; García-Almagro D; Sejas AG
J Dermatol; 2012 May; 39(5):503-5. PubMed ID: 21973079
[No Abstract] [Full Text] [Related]
39. Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK.
Afzal UM; Ghadiri SJ; Sambi P; Muinonen-Martin A; Mitra A
Clin Exp Dermatol; 2024 Jan; 49(2):163-165. PubMed ID: 37758510
[No Abstract] [Full Text] [Related]
40. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.
Chapman MS; Spencer SK; Brennick JB
Arch Dermatol; 2003 Jul; 139(7):943-4. PubMed ID: 12873902
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
